ClinicalTrials.gg
CompletedNCT02607930Updated Mar 2, 2022Results posted

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

A Phase 3 interventional study of ABC/DTG/3TC and B/F/TAF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 121 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-02.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
631
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus a FDC containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) in HIV-1 infected, antiretroviral treatment naive-adults.

02

Conditions studied

  • HIV-1 Infection

Keywords

  • HIV
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Antiretroviral treatment naive (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of -1 infection) except the use for pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP), up to one month prior to screening
  • Plasma HIV-1 ribonucleic acid (RNA) levels ≥ 500 copies per milliliter (mL) at screening
  • Adequate renal function: Estimated ≥ 50 milliliter per minute (mL/min) (≥ 0.83 milliliter per second [mL/sec]) according to the formula
  • Negative screening test for human leukocyte antigen (HLA) -B x 5701 allele provided by Gilead Sciences

Key Exclusion Criteria:

  • An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening (refer to study protocol)
  • Decompensated cirrhosis (e.g, ascites, encephalopathy, or variceal bleeding)
  • Current alcohol or substance use judged by the Investigator to potentially interfere with subject study compliance
  • Females who are pregnant (as confirmed by positive serum pregnancy test)
  • Females who are breastfeeding
  • Chronic Virus (HBV) infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
631 participants (actual)

Study arms

  • Experimental
    B/F/TAF

    B/F/TAF + ABC/DTG/3TC placebo administered without regard to food for at least 144 weeks.

    Drug: B/F/TAF · Drug: ABC/DTG/3TC Placebo

  • Active comparator
    ABC/DTG/3TC

    ABC/DTG/3TC + B/F/TAF placebo administered without regard to food for at least 144 weeks.

    Drug: ABC/DTG/3TC · Drug: B/F/TAF Placebo

  • Experimental
    Open-label Phase B/F/TAF to B/F/TAF

    After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.

    Drug: B/F/TAF

  • Experimental
    Open-label Phase ABC/DTG/3TC to B/F/TAF

    After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive OL B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.

    Drug: B/F/TAF

Interventions

  • DrugABC/DTG/3TC

    600/50/300 milligrams (mg) tablets administered orally, once daily

    Also known as: Triumeq®

  • DrugB/F/TAF

    Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide

    50/200/25 mg tablets administered orally, once daily, without regard to food

    Also known as: GS-9883/F/TAF, Biktarvy®

  • DrugABC/DTG/3TC Placebo

    Tablets administered orally, once daily

  • DrugB/F/TAF Placebo

    Tablets administered orally, once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 96

  2. Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 144

  3. Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  4. Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 96

  5. Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 144

  6. Change From Baseline in log10 HIV-1 RNA at Week 48

    Time frame: Baseline, Week 48

  7. Change From Baseline in log10 HIV-1 RNA at Week 96

    Time frame: Baseline, Week 96

  8. Change From Baseline in log10 HIV-1 RNA at Week 144

    Time frame: Baseline, Week 144

  9. Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline, Week 48

  10. Change From Baseline in CD4+ Cell Count at Week 96

    Time frame: Baseline, Week 96

  11. Change From Baseline in CD4+ Cell Count at Week 144

    Time frame: Baseline, Week 144

  12. Percentage Change From Baseline in Hip BMD at Week 48

    Time frame: Baseline, Week 48

  13. Percentage Change From Baseline in Hip BMD at Week 96

    Time frame: Baseline, Week 96

  14. Percentage Change From Baseline in Hip BMD at Week 144

    Time frame: Baseline, Week 144

  15. Percentage Change From Baseline in Spine BMD at Week 48

    Time frame: Baseline, Week 48

  16. Percentage Change From Baseline in Spine BMD at Week 96

    Time frame: Baseline, Week 96

  17. Percentage Change From Baseline in Spine BMD at Week 144

    Time frame: Baseline, Week 144

  18. Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Excluded Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with non-missing HIV-1 RNA value at that visit.

    Time frame: Baseline, open-label Week 48

  19. Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Failure Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set.

    Time frame: Baseline, open-label Week 48

  20. Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Excluded Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with non-missing HIV-1 RNA value at that visit.

    Time frame: Baseline, open-label Week 96

  21. Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Failure Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set.

    Time frame: Baseline, open-label Week 96

  22. Change From Baseline in CD4+ Cell Count at Week 48 Open-Label

    Time frame: Baseline, open-label Week 48

  23. Change From Baseline in CD4+ Cell Count at Week 96 Open-Label

    Time frame: Baseline, open-label Week 96

07

Results

Posted Jul 23, 2018

Participant flow

Participants were enrolled at study centers in Europe, Dominican Republic, and North America. The first participant was screened on 13 November 2015. The last study visit occurred on 02 July 2021.

Double-Blinded Treatment Phase
Participant flow — Double-Blinded Treatment Phase
MilestoneB/F/TAFABC/DTG/3TCB/F/TAF to B/F/TAFABC/DTG/3TC to B/F/TAF
Started31631500
Completed26226200
Not completed545300
Withdrew: Lost to follow-up251900
Withdrew: Withdrew consent141800
Withdrew: Investigator's discretion6300
Withdrew: Non-compliance with study drug3500
Withdrew: Protocol violation2300
Withdrew: Adverse event0400
Withdrew: Death2100
Withdrew: Randomized but never treated2000
Open-Label B/F/TAF Extension Phase
Participant flow — Open-Label B/F/TAF Extension Phase
MilestoneB/F/TAFABC/DTG/3TCB/F/TAF to B/F/TAFABC/DTG/3TC to B/F/TAF
Started00252254
Completed00218221
Not completed003433
Withdrew: Lost to follow-up001510
Withdrew: Withdrew consent001013
Withdrew: Investigator's discretion0025
Withdrew: Adverse event0042
Withdrew: Lack of efficacy0011
Withdrew: Protocol violation0011
Withdrew: Death0001
Withdrew: Non-compliance with study drug0010

Outcome measures

PrimaryPercentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAFABC/DTG/3TC
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm92.493.0
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · Difference in percentages: -0.6 · 95.002% CI -4.8 to 3.6Differences in percentages of participants between groups and their 95.002% CIs were calculated based on Mantel-Haenszel (MH) proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
  • B/F/TAF vs ABC/DTG/3TC · Cochran-Mantel-Haenszel · p = 0.78p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAFABC/DTG/3TC
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm87.989.8
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · Difference in percentages: -1.9 · 95% CI -6.9 to 3.1Differences in percentages of participants between groups and their 95% CIs were calculated based on Mantel-Haenszel (MH) proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
  • B/F/TAF vs ABC/DTG/3TC · Cochran-Mantel-Haenszel · p = 0.45p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 144
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAFABC/DTG/3TC
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm81.584.1
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · Difference in percentages: -2.6 · 95% CI -8.5 to 3.4Differences in percentages of participants between groups and their 95% CIs were calculated based on MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
  • B/F/TAF vs ABC/DTG/3TC · Cochran-Mantel-Haenszel · p = 0.39p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAFABC/DTG/3TC
Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm87.687.3
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · Difference in percentages: 0.4 · 95% CI -4.8 to 5.6The differences in percentages of participants between treatment groups and their 95% CIs were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
  • B/F/TAF vs ABC/DTG/3TC · Cochran-Mantel-Haenszel · p = 0.87p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAFABC/DTG/3TC
Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm83.484.8
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · Difference in percentages: -1.2 · 95% CI -6.9 to 4.6The differences in percentages of participants between treatment groups and their 95% CIs were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
  • B/F/TAF vs ABC/DTG/3TC · Cochran-Mantel-Haenszel · p = 0.69p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 144
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAFABC/DTG/3TC
Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm78.082.2
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · Difference in percentages: -4.2 · 95% CI -10.5 to 2.1The differences in percentages of participants between treatment groups and their 95% CIs were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
  • B/F/TAF vs ABC/DTG/3TC · Cochran-Mantel-Haenszel · p = 0.19p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
SecondaryChange From Baseline in log10 HIV-1 RNA at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · log10 copies/mL
Change From Baseline in log10 HIV-1 RNA at Week 48
log10 copies/mLB/F/TAFABC/DTG/3TC
Change From Baseline in log10 HIV-1 RNA at Week 48-3.11 ± 0.641-3.07 ± 0.738
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · ANOVA · p = 0.48 · Difference in lsm: -0.03 · 95% CI -0.12 to 0.06Difference in least-squares mean (LSM), and its 95% confidence interval (CI) were adjusted by baseline HIV-1 RNA stratum and region stratum.
SecondaryChange From Baseline in log10 HIV-1 RNA at Week 96
Time frame:
Baseline, Week 96
Reported as:
Mean · log10 copies/mL
Change From Baseline in log10 HIV-1 RNA at Week 96
log10 copies/mLB/F/TAFABC/DTG/3TC
Change From Baseline in log10 HIV-1 RNA at Week 96-3.09 ± 0.643-3.10 ± 0.705
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · ANOVA · p = 0.99 · Difference in lsm: 0.00 · 95% CI -0.09 to 0.09Difference in LSM, and its 95% CI were adjusted by baseline HIV-1 RNA stratum and region stratum.
SecondaryChange From Baseline in log10 HIV-1 RNA at Week 144
Time frame:
Baseline, Week 144
Reported as:
Mean · log10 copies/mL
Change From Baseline in log10 HIV-1 RNA at Week 144
log10 copies/mLB/F/TAFABC/DTG/3TC
Change From Baseline in log10 HIV-1 RNA at Week 144-3.11 ± 0.639-3.10 ± 0.681
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · ANOVA · p = 0.88 · Difference in lsm: 0.01 · 95% CI -0.08 to 0.10Difference in LSM, and its 95% CI were adjusted by baseline HIV-1 RNA stratum and region stratum.
SecondaryChange From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 48
cells/µLB/F/TAFABC/DTG/3TC
Change From Baseline in CD4+ Cell Count at Week 48235 ± 185.8228 ± 188.7
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · ANOVA · p = 0.69 · Difference in lsm: 6 · 95% CI -24 to 36Difference in LSM, and its 95% CI were adjusted by the baseline HIV-1 RNA and region stratum.
SecondaryChange From Baseline in CD4+ Cell Count at Week 96
Time frame:
Baseline, Week 96
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 96
cells/µLB/F/TAFABC/DTG/3TC
Change From Baseline in CD4+ Cell Count at Week 96287 ± 206.9288 ± 246.8
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · ANOVA · p = 0.94 · Difference in lsm: -1 · 95% CI -39 to 36Difference in LSM, and its 95% CI were adjusted by the baseline HIV-1 RNA and region stratum.
SecondaryChange From Baseline in CD4+ Cell Count at Week 144
Time frame:
Baseline, Week 144
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 144
cells/µLB/F/TAFABC/DTG/3TC
Change From Baseline in CD4+ Cell Count at Week 144299 ± 224.9317 ± 219.5
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · ANOVA · p = 0.30 · Difference in lsm: -20 · 95% CI -59 to 18Difference in LSM, and its 95% CI were adjusted by baseline HIV-1 RNA stratum and region stratum.
SecondaryPercentage Change From Baseline in Hip BMD at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · percentage change
Percentage Change From Baseline in Hip BMD at Week 48
percentage changeB/F/TAFABC/DTG/3TC
Percentage Change From Baseline in Hip BMD at Week 48-0.802 ± 2.3280-1.148 ± 2.5126
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · ANOVA · p = 0.092 · Difference in lsm: 0.346 · 95% CI -0.057 to 0.748
SecondaryPercentage Change From Baseline in Hip BMD at Week 96
Time frame:
Baseline, Week 96
Reported as:
Mean · percentage change
Percentage Change From Baseline in Hip BMD at Week 96
percentage changeB/F/TAFABC/DTG/3TC
Percentage Change From Baseline in Hip BMD at Week 96-1.128 ± 2.7702-1.262 ± 2.8524
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · ANOVA · p = 0.59 · Difference in lsm: 0.135 · 95% CI -0.356 to 0.625
SecondaryPercentage Change From Baseline in Hip BMD at Week 144
Time frame:
Baseline, Week 144
Reported as:
Mean · percentage change
Percentage Change From Baseline in Hip BMD at Week 144
percentage changeB/F/TAFABC/DTG/3TC
Percentage Change From Baseline in Hip BMD at Week 144-1.020 ± 3.7638-1.291 ± 3.1140
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · ANOVA · p = 0.39 · Difference in lsm: 0.271 · 95% CI -0.351 to 0.893
SecondaryPercentage Change From Baseline in Spine BMD at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · percentage change
Percentage Change From Baseline in Spine BMD at Week 48
percentage changeB/F/TAFABC/DTG/3TC
Percentage Change From Baseline in Spine BMD at Week 48-0.772 ± 3.2228-0.552 ± 3.0956
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · ANOVA · p = 0.41 · Difference in lsm: -0.221 · 95% CI -0.741 to 0.300
SecondaryPercentage Change From Baseline in Spine BMD at Week 96
Time frame:
Baseline, Week 96
Reported as:
Mean · percentage change
Percentage Change From Baseline in Spine BMD at Week 96
percentage changeB/F/TAFABC/DTG/3TC
Percentage Change From Baseline in Spine BMD at Week 96-0.705 ± 3.8721-0.219 ± 3.5159
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · ANOVA · p = 0.14 · Difference in lsm: -0.485 · 95% CI -1.126 to 0.155
SecondaryPercentage Change From Baseline in Spine BMD at Week 144
Time frame:
Baseline, Week 144
Reported as:
Mean · percentage change
Percentage Change From Baseline in Spine BMD at Week 144
percentage changeB/F/TAFABC/DTG/3TC
Percentage Change From Baseline in Spine BMD at Week 144-0.371 ± 4.43690.035 ± 3.5182
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · ANOVA · p = 0.26 · Difference in lsm: -0.406 · 95% CI -1.119 to 0.307
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Excluded Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with non-missing HIV-1 RNA value at that visit.

Time frame:
Baseline, open-label Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Excluded Algorithm
percentage of participantsAll B/F/TAFABC/DTG/3TC to B/F/TAF
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Excluded Algorithm99.2 (97.0 to 99.9)100 (98.3 to 100.0)
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Failure Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set.

Time frame:
Baseline, open-label Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Failure Algorithm
percentage of participantsAll B/F/TAFABC/DTG/3TC to B/F/TAF
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Failure Algorithm74.8 (69.7 to 79.5)83.5 (78.3 to 87.8)
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Excluded Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with non-missing HIV-1 RNA value at that visit.

Time frame:
Baseline, open-label Week 96
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Excluded Algorithm
percentage of participantsAll B/F/TAFABC/DTG/3TC to B/F/TAF
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Excluded Algorithm97.7 (94.6 to 99.2)99.5 (97.5 to 100.0)
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Failure Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set.

Time frame:
Baseline, open-label Week 96
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Failure Algorithm
percentage of participantsAll B/F/TAFABC/DTG/3TC to B/F/TAF
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Failure Algorithm66.2 (60.7 to 71.5)85.4 (80.5 to 89.5)
SecondaryChange From Baseline in CD4+ Cell Count at Week 48 Open-Label
Time frame:
Baseline, open-label Week 48
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 48 Open-Label
cells/µLAll B/F/TAFABC/DTG/3TC to B/F/TAF
Change From Baseline in CD4+ Cell Count at Week 48 Open-Label330 ± 242.8-4 ± 202.0
SecondaryChange From Baseline in CD4+ Cell Count at Week 96 Open-Label
Time frame:
Baseline, open-label Week 96
Reported as:
Mean · cell/µL
Change From Baseline in CD4+ Cell Count at Week 96 Open-Label
cell/µLAll B/F/TAFABC/DTG/3TC to B/F/TAF
Change From Baseline in CD4+ Cell Count at Week 96 Open-Label339 ± 237.8-15 ± 188.1

Adverse events

Collected over Adverse Events: First dose date up to last dose date (maximum: 279 weeks) plus 30 days All-Cause Mortality: Randomization date through last visit/follow up date (maximum duration: 282.4 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B/F/TAF2/316 (0.6%)44/314 (14%)262/314 (83.4%)
ABC/DTG/3TC1/315 (0.3%)54/315 (17.1%)276/315 (87.6%)
B/F/TAF to B/F/TAF2/252 (0.8%)19/252 (7.5%)152/252 (60.3%)
ABC/DTG/3TC to B/F/TAF2/254 (0.8%)19/254 (7.5%)153/254 (60.2%)
Most frequent serious events
Showing 10 of 158
Most frequent serious events
EventB/F/TAFABC/DTG/3TCB/F/TAF to B/F/TAFABC/DTG/3TC to B/F/TAF
AppendicitisInfections and infestations3/3142/3150/2520/254
Major depressionPsychiatric disorders3/3140/3150/2520/254
Suicidal ideationPsychiatric disorders3/3143/3151/2521/254
Road traffic accidentInjury, poisoning and procedural complications0/3143/3150/2521/254
Covid-19Infections and infestations0/3140/3152/2520/254
CellulitisInfections and infestations1/3140/3150/2522/254
Acute kidney injuryRenal and urinary disorders0/3141/3150/2522/254
AnaemiaBlood and lymphatic system disorders2/3140/3150/2521/254
HaematemesisGastrointestinal disorders2/3140/3150/2520/254
Chest painGeneral disorders2/3142/3150/2521/254
Most frequent other events
Showing 10 of 34
Most frequent other events
EventB/F/TAFABC/DTG/3TCB/F/TAF to B/F/TAFABC/DTG/3TC to B/F/TAF
NauseaGastrointestinal disorders40/31477/3158/2527/254
Upper respiratory tract infectionInfections and infestations46/31461/31516/25219/254
DiarrhoeaGastrointestinal disorders54/31457/3156/25213/254
HeadacheNervous system disorders44/31456/3158/2529/254
NasopharyngitisInfections and infestations41/31452/31518/25214/254
SyphilisInfections and infestations43/31451/31522/25222/254
Back painMusculoskeletal and connective tissue disorders35/31443/31515/25215/254
FatigueGeneral disorders35/31441/3157/25211/254
ArthralgiaMusculoskeletal and connective tissue disorders36/31441/31513/25212/254
InsomniaPsychiatric disorders27/31435/3158/2525/254

Baseline characteristics

Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)B/F/TAFABC/DTG/3TCTotal
Mean34 ± 10.934 ± 10.834 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)B/F/TAFABC/DTG/3TCTotal
Female293362
Male285282567
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)B/F/TAFABC/DTG/3TCTotal
Race — American Indian or Alaska Native246
Race — Asian61016
Race — Black114112226
Race — Native Hawaiian or Pacific Islander123
Race — White180179359
Race — Other9817
Race — Not Permitted202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)B/F/TAFABC/DTG/3TCTotal
Ethnicity — Hispanic or Latino7265137
Ethnicity — Not Hispanic or Latino240249489
Ethnicity — Not Permitted213
Region of Enrollment
Region of Enrollment(Participants)B/F/TAFABC/DTG/3TCTotal
Canada181533
Belgium426
United States228233461
Dominican Republic213
Italy71118
United Kingdom201131
France111021
Germany4913
Spain202343
HIV-1 RNA
HIV-1 RNA(log10 copies/mL)B/F/TAFABC/DTG/3TCTotal
Mean4.41 ± 0.6474.42 ± 0.6854.42 ± 0.665
HIV-1 RNA Categories
HIV-1 RNA Categories(Participants)B/F/TAFABC/DTG/3TCTotal
≤ 100,000 copies/mL261265526
> 100,000 ≤ 400,000 copies/mL453883
> 400,000 copies/mL81220
CD4 Cell Count
CD4 Cell Count(Cells/µL)B/F/TAFABC/DTG/3TCTotal
Mean453 ± 220.8476 ± 231.4464 ± 226.3

3 further baseline measures are reported on the registry.

08

Study locations

121 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-2050, United States
  • Spectrum Medical Group
    Phoenix, Arizona 85012, United States
  • Pueblo Family Physicians
    Phoenix, Arizona 85015, United States
  • Kaiser Permanente Medical Center
    Los Angeles, California 90027, United States
  • Ruane Clinical Research Group, Inc.
    Los Angeles, California 90036, United States
  • Anthony Martin Mills MD A Medical Corporation, DBA Mills Clinical Research
    Los Angeles, California 90069, United States
  • Alameda Health System- Highland Hospital
    Oakland, California 94602, United States
  • University of California Davis
    Sacramento, California 95817, United States
  • Kaiser Permanente Medical Group
    Sacramento, California 95825, United States
  • La Playa Medical Group
    San Diego, California 92103, United States
  • Kaiser Permanente
    San Francisco, California 94118, United States
  • Kaiser Permanente
    San Leandro, California 94577, United States
  • The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • Apex Research
    Denver, Colorado 80209, United States
  • Whitman-Walker Institute
    Washington, District of Columbia 20009, United States
  • Providence Hospital - DC
    Washington, District of Columbia 20017, United States
  • Capital Medical Associates
    Washington, District of Columbia 20036, United States
  • Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • Therafirst Medical Center
    Fort Lauderdale, Florida 33308, United States
  • Gary J. Richmond, M.D., P.A.
    Fort Lauderdale, Florida 33316, United States
  • Midway Immunology and Research Center
    Fort Pierce, Florida 34982, United States
  • AHF Kinder Medical Group
    Miami, Florida 33133, United States
  • Miami, Florida 33140, United States
  • Orlando Immunology Center
    Orlando, Florida 32803, United States
  • AIDS Healthcare Foundation-Miami Beach
    Pensacola, Florida 32504, United States
  • St. Joseph's Comprehensive Research Institute
    Tampa, Florida 33614, United States
  • AIDS Research and Treatment Center of the Treasure Coast
    Vero Beach, Florida 32960, United States
  • Triple O Research Institute PA
    West Palm Beach, Florida 33401, United States
  • Emory University
    Atlanta, Georgia 30308, United States
  • Atlanta Infectious Disease Group PC
    Atlanta, Georgia 30309, United States
  • Aids Research Consortium of Atlanta Inc
    Atlanta, Georgia 30312, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Infectious Disease Specialists of Atlanta
    Decatur, Georgia 30033, United States
  • Chatham County Health Department
    Savannah, Georgia 31401, United States
  • Indiana CTSI Clinical Research Center
    Indianapolis, Indiana 46202, United States
  • Louisiana State University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Baystate Medical Center
    Springfield, Massachusetts 01199, United States
  • Be Well Medical Center
    Berkley, Michigan 48072, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota 55415, United States
  • Kansas City CARE Clinic
    Kansas City, Missouri 64111, United States
  • Southampton Clinical Research Group, Inc.
    Saint Louis, Missouri 63108, United States
  • Southampton Healthcare Inc
    Saint Louis, Missouri 63139, United States
  • Prime healthcare services - St Michael's LLC d/b/a Saint Michael's medical center
    Newark, New Jersey 07102, United States
  • South Jersey Infectious Disease
    Somers Point, New Jersey 08244, United States
  • Santa Fe, New Mexico 87505, United States
  • Upstate Infectious Disease Associates
    Albany, New York 12208, United States
  • Bronx Care
    Bronx, New York 10457, United States
  • Montefiore Medical Center
    Bronx, New York 10467-2490, United States
  • Evergreen Health
    Buffalo, New York 14215, United States
  • North Shore University Hospital-(Manhasset)
    Manhasset, New York 11030, United States
  • Aids Research Consortium of Atlanta Inc
    Chapel Hill, North Carolina 27514, United States
  • ID Consultants PA
    Charlotte, North Carolina 28209, United States
  • Greensboro, North Carolina 27401, United States
  • East Carolina University
    Greenville, North Carolina 27858-4354, United States
  • Rosedale Infectious Diseases
    Huntersville, North Carolina 28078, United States
  • Wake Forest Baptist Medical Center - PPDS
    Winston-Salem, North Carolina 27157-1042, United States
  • Summa Health System
    Akron, Ohio 44304, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • MetroHealth Research Institute
    Cleveland, Ohio 44109, United States
  • Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Philadelphia FIGHT
    Philadelphia, Pennsylvania 19107, United States
  • Allegheny Health Network
    Pittsburgh, Pennsylvania 15212, United States
  • Medical University of South Carolina PPDS
    Columbia, South Carolina 29203-6840, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • Saint Hope Foundation Inc
    Bellaire, Texas 77401, United States
  • AIDS Arms Inc
    Dallas, Texas 75215, United States
  • UT Southwestern Clinical Trials Office
    Dallas, Texas 75235, United States
  • North Texas Infectious Diseases Consultants PA
    Dallas, Texas 75246, United States
  • Fort Worth, Texas 76104, United States
  • Therapeutic Concepts
    Houston, Texas 77004, United States
  • Gordon E Crofoot MD PA
    Houston, Texas 77098, United States
  • Research Access Network
    Houston, Texas 77098, United States
  • Diagnostic Clinic of Longview Center For Clinical Research (DCOL)
    Longview, Texas 75605, United States
  • Peter Shalit MD
    Seattle, Washington 98104, United States
  • Multicare Rockwood HIV Critical Care Clinic
    Spokane, Washington 99204, United States
  • The Medical College of Wisconsin, Inc.
    Milwaukee, Wisconsin 53226, United States
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • UZ Gent
    Ghent, B-9000, Belgium
  • Clinique Medicale L'actuel
    Montreal, H2L 5B1, Canada
  • McGill University Health Center
    Montreal, H2X 2P4, Canada
  • Clinique OPUS Inc
    Montreal, H3A 1T1, Canada
  • Ottawa Hospital
    Ottawa, K1H 8L6, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, M4N 3M5, Canada
  • Maple Leaf Research
    Toronto, M5G 1K2, Canada
  • Spectrum Health Care
    Vancouver, V6Z 2T1, Canada
  • Winnipeg Regional Health Authority
    Winnipeg, R3A 1R9, Canada
  • Instituto Dominicano de Estudios Virologicos IDEV
    Santo Domingo, 10103, Dominican Republic
  • Hôpital de La Croix Rousse
    Lyon cedex 04, 69317, France
  • CHU de Nice Archet I
    Nice, 06200, France
  • Hôpital Saint Louis
    PARIS cedex 10, 75475, France
  • Paris, 75018, France
  • Hôpital Saint Antoine
    Paris, 75571, France
  • Groupe Hospitalier Bichat Claude Bernard
    Tourcoing, 59208, France
  • zibp Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH
    Berlin, 13353, Germany
  • Universitätsklinikum Bonn
    Bonn, 53127, Germany
  • ICH Study Center
    Hamburg, 20146, Germany
  • ASST Papa Giovanni XXIII - Azienda Ospedaliera Papa Giovanni XXIII
    Bergamo, 24127, Italy
  • Ospedale San Raffaele S.r.l. - PPDS
    Milano, 20127, Italy

Showing the first 100 of 121 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Wohl D, Clarke A, Maggiolo F, Garner W, Laouri M, Martin H, Quirk E. Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine. Patient. 2018 Oct;11(5):561-573. doi: 10.1007/s40271-018-0322-8. PubMed 29956087 ↗
  • Wohl DA, Yazdanpanah Y, Baumgarten A, Clarke A, Thompson MA, Brinson C, Hagins D, Ramgopal MN, Antinori A, Wei X, Acosta R, Collins SE, Brainard D, Martin H. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019 Jun;6(6):e355-e363. doi: 10.1016/S2352-3018(19)30077-3. Epub 2019 May 5. PubMed 31068270 ↗
  • Acosta RK, Willkom M, Martin R, Chang S, Wei X, Garner W, Lutz J, Majeed S, SenGupta D, Martin H, Quirk E, White KL. Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks. Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02533-18. doi: 10.1128/AAC.02533-18. Print 2019 May. PubMed 30803969 ↗
  • Acosta R, Willkom M, Martin R, Chang S, Liu X, Hedskog C, et al. Low-frequency resistance variants in art-naïve participants do not affect bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) triple therapy outcome. [Poster MOPEB242]. 10th IAS Conference on HIV Science (IAS 2019); 2019 July 21-24; Mexico City, Mexico.
  • Acosta R, White K, Garner W, Wei X, Andreatta K, Willkom M, et al. HIV-1 subtype (B or non-B) had no impact on the efficacy of B/F/TAF or resistance development in five phase 3 treatment-naïve or switch studies. [Poster THPEB077]. 22nd International AIDS Conference; 2018 July 23-27; Amsterdam, Netherlands.
  • White K, Kulkarni R, Willkom M, Martin R, Chang S, Wei X, et al. Pooled week 48 efficacy and baseline resistance: B/F/TAF in treatment-naive patients. [Poster 532]. Conference on Retroviruses and Opportunistic Infections; 2018 March 4-7; Boston, USA.
  • Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31. PubMed 28867497 ↗
  • Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H; GS-US-380-1489; GS-US-380-1490 study investigators. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0. PubMed 32504574 ↗
  • Acosta R, Andreatta K, D'Antoni M, Collins S, Martin H, White K. HIV Viral Blips in Adults Treated with INSTI-Based Regimens Through 144 Weeks. [Poster 540]. Conference on Retroviruses and Opportunistic Infections 2020 (CROI 2020); 2020 March 8-11; Boston, Massachusetts.
  • Mills A, Gupta SK, Brinson C, Workowski K, Clarke A, Antinori A, Stephens JL, et al. 144-Week Efficacy and Safety of B/F/TAF in Treatment-Naive Adults Age ≥50 Years. [Poster 477]. Conference on Retroviruses and Opportunistic Infections 2020 (CROI 2020); 2020 March 8-11; Boston, Massachusetts.
  • Ramgopal M, Maggiolo F, Ward D, Leboucche B, Rizzardini G, Molina JM, et al. Pooled Analysis of 4 International Trials of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Adults Aged ≥ 65 Years Demonstrating Safety and Efficacy: Week 48 Results. [Oral OAB0403].AIDS 2020; 2020 July 6-10; Virtual.
  • Acosta R, Andreatta K, D'Antoni M, Collins S, Martin H, White K. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) shows high efficacy in clinical study participants infected with HIV-1 subtype F. [Poster P124]. HIV Drug Therapy 2020 (HIV Glasgow 2020); 2020 October 5-8; Glasgow, United Kingdom.
  • Workowski K, Orkin C, Sax P, Hagins D, Koenig E, Stephens JL, et al. Four-Year Outcomes of B/F/TAF in Treatment-Naïve Adults [Poster 415]. Conference on Retroviruses and Opportunistic Infections 2021 (CROI 2021); 2021 June 3-November 3; Virtual.
  • Acosta RK, Chen GQ, Chang S, Martin R, Wang X, Huang H, Brainard D, Collins SE, Martin H, White KL. Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants. J Antimicrob Chemother. 2021 Jul 15;76(8):2153-2157. doi: 10.1093/jac/dkab115. PubMed 33880558 ↗
  • Arribas J, Orkin C, Maggiolo F, Antinori A, Lazzarin A, Yasdanpanah, et al. Long-term Analysis of B/F/TAF in Treatment-Naïve Adults Living With HIV Through Four Years of Follow-up. [PEB151]. 11th IAS Conference on HIV Science (IAS 2021); 2021 July 18-21; Virtual.
  • Acosta R, Chen G, Qin L, Wang X, Huang H, Hindman J, et al. Achievement of Undetectable HIV-1 RNA in the B/F/TAF Treatment-Naïve Clinical Trials. [Poster PEB150]. 11th IAS Conference on HIV Science (IAS 2021); 2021 July 18-21; Virtual.
  • Acosta R, Chen G, Chang S, Martin R, Wang X, Huang H, et al. HIV with Transmitted Drug Resistance Is Durably Suppressed by B/F/TAF at Week 144. [Poster 430]. Conference on Retroviruses and Opportunistic Infections 2021 (CROI 2021); 2021 June 3-November 3; Virtual.
  • Acosta R, Chen G, Huang H, Liu H, White K. Unreturned Pill Bottles in the 1489 and 1490 Clinical Trials: An Important Measure of Poor Adherence That Is Often Ignored in Pill Count Calculations. [Poster 902]. IDWeek 2021; 2021 September 29-October 3; Virtual.
  • Daar E, Orkin C, Sax P, Stephens J, Koenig E, Clarke A, et al. Incidence of Metabolic Complications Among Treatment-naïve Adults Living With HIV-1 Randomized to B/F/TAF, DTG/ABC/3TC or DTG + F/TAF After 3 Years. [Oral 69]. IDWeek 2021; 2021 September 29-October 3; Virtual.
  • Pozniak A, et al. Outcomes 48 Weeks After Switching From DTG/ABC/3TC or DTG + F/TAF to B/F/TAF. [PE2/68]. 18th European AIDS Conference (EAC 2021), 2021 October 27-30; London, United Kingdom.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy/

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in May 2017, 17 months.

Results were first posted in Jul 2018, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2015
First posted
Nov 18, 2015
StartActual
Nov 13, 2015
Primary completionActual
May 9, 2017
CompletionActual
Jul 2, 2021
Results first posted
Jul 23, 2018
Last update
Mar 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02607930
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 18, 2015
Start date
Nov 13, 2015
Primary completion
May 9, 2017
Completion
Jul 2, 2021
Results posted
Jul 23, 2018
Last update
Mar 2, 2022

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide

Start the discussion